Compare
Novavax Inc vs Bio-Techne Corp vs Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals Inc
| Latest fiscal year | Novavax Inc NVAX | Bio-Techne Corp TECH | Halozyme Therapeutics, Inc. HALO | BioCryst Pharmaceuticals Inc BCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.12B | $1.22B | $1.40B | $874.84M |
| Revenue growth (YoY) | +64.7% | -0.4% | +37.6% | +94.1% |
| Gross margin | 93.5% (computed) | 65.8% | 83.6% (computed) | n/a |
| Operating margin | 40.3% | 20.7% | 33.6% | 39.0% |
| Net margin | 39.2% | 15.0% | 22.7% | 30.2% |
| Net income | $440.30M | $181.86M | $316.89M | $263.86M |
| EPS (Diluted) | $2.58 | $1.16 | $2.56 | $1.21 |
| Operating cash flow | -$244.63M | $292.07M | $651.56M | $347.37M |
| Free cash flow | n/a | $263.22M | $644.59M | $344.90M |
| Cash & equivalents | $240.63M | $264.71M | $133.82M | $89.74M |
| Total assets | $1.18B | $2.59B | $2.53B | $514.16M |
| Total liabilities | $1.30B | n/a | $2.48B | $633.31M |
| Shareholders' equity | -$127.75M | $2.11B | $48.81M | -$119.15M |
| Return on year-end equity | n/a | 8.6% | 649.2% | n/a |
| Shares outstanding | 162.58M | 156.10M | 117.78M | 213.06M |
Revenue, most recent five fiscal years
| Fiscal year | Novavax Inc | Bio-Techne Corp | Halozyme Therapeutics, Inc. | BioCryst Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $1.12B Ended 2025-12-31 | $1.22B Ended 2026-06-30 | $1.40B Ended 2025-12-31 | $874.84M Ended 2025-12-31 |
| 1 year earlier | $682.16M Ended 2024-12-31 | $1.22B Ended 2025-06-30 | $1.02B Ended 2024-12-31 | $450.71M Ended 2024-12-31 |
| 2 years earlier | $983.71M Ended 2023-12-31 | $1.16B Ended 2024-06-30 | $829.25M Ended 2023-12-31 | $331.41M Ended 2023-12-31 |
| 3 years earlier | $1.98B Ended 2022-12-31 | $1.14B Ended 2023-06-30 | $660.12M Ended 2022-12-31 | $270.83M Ended 2022-12-31 |
| 4 years earlier | $1.15B Ended 2021-12-31 | $1.11B Ended 2022-06-30 | $443.31M Ended 2021-12-31 | $157.17M Ended 2021-12-31 |